US 12,435,095 B2
Substituted morpholines as ATR kinase inhibitors
Kai Long, Shanghai (CN)
Assigned to Shanghai Annova Biotechnology Co., Ltd., Shanghai (CN)
Appl. No. 18/723,033
Filed by Shanghai Annova Biotechnology Co., Ltd., Shanghai (CN)
PCT Filed Dec. 19, 2022, PCT No. PCT/CN2022/139864
§ 371(c)(1), (2) Date Aug. 29, 2024,
PCT Pub. No. WO2023/116594, PCT Pub. Date Jun. 29, 2023.
Claims priority of application No. 202111571407.6 (CN), filed on Dec. 21, 2021.
Prior Publication US 2025/0051362 A1, Feb. 13, 2025
Int. Cl. A61K 31/5377 (2006.01); A61P 35/00 (2006.01); C07D 265/30 (2006.01); C07D 471/04 (2006.01); C07D 487/04 (2006.01); C07D 519/00 (2006.01)
CPC C07D 519/00 (2013.01) [A61K 31/5377 (2013.01); A61P 35/00 (2018.01); C07D 471/04 (2013.01); C07D 487/04 (2013.01)] 5 Claims
 
1. A compound of formula I:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof,
wherein:

OG Complex Work Unit Chemistry
R1 is:

OG Complex Work Unit Chemistry
wherein the pyrrolo[2,3-b]pyridinyl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, CN, CH3, C(O) NH2, NH2, NHCH3, N(CH3)2, OH, and OCH3; and
R2 is CH3.
 
5. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the compound according to claim 1, or a pharmaceutically acceptable salt thereof.